Theralase Technologies ( #TSXV: $TLT | #OTCQB: #TLTFF ) is developing a light-activated drug designed to target cancer cells. CEO Roger White shared the case of a study patient who retained their bladder seven years after a single treatment.
Watch: youtu.be/yeFJUx2w9d8?...
